"A class of medications long used to curb HIV infection shows promise as a therapy for age-related macular degeneration (AMD), suggest findings from an NIH-funded study. These mainstay HIV drugs, called nucleoside reverse transcriptase inhibitors "...
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. LUMIGAN® 0.03% (bimatoprost ophthalmic solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
LUMIGAN® 0.03% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Dosage Forms And Strengths
Ophthalmic solution containing bimatoprost 0.3 mg/mL
Storage And Handling
LUMIGAN® (bimatoprost ophthalmic solution) 0.03% is supplied sterile in opaque white low density polyethylene ophthalmic dispenser bottles and tips with turquoise polystyrene caps in the following sizes:
2.5 mL fill in 5 mL container -NDC 0023-9187-03
5 mL fill in 10 mL container -NDC 0023-9187-05
7.5 mL fill in 10 mL container -NDC 0023-9187-07
Store at 2°-25°C (36°-77°F).
Allergan, Inc. Irvine, CA 92612. Revised: 09/2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/20/2014
Additional Lumigan Information
Lumigan - User Reviews
Lumigan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.